Breakthrough Designation for Compound for Relapsed or Refractory Hodgkin's

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has granted their latest potential treatment for some Hodgkin's patients Breakthrough Therapy Designation.

The company has received the designation for its investigational PD-1 immune checkpoint inhibitor nivolumab, based on data from a cohort of patients with HL in the company's ongoing Phase 1b study of relapsed and refractory hematological malignancies.

Nivolumab is an investigational, fully-human PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T-cells.

Bristol-Meyers Squibb is exploring the compound for the treatment of patients with Hodgkin's lymphoma (HL) who have had both an autologous stem cell transplant and received brentuximab (Adcetris).

"The Breakthrough Therapy Designation granted by the FDA for nivolumab continues to support the development of innovative approaches designed to advance how cancer is treated," said Michael Giordano, senior vice president, Head of Development, Oncology & Immunosciences. "It is our goal to change the way patients live with cancer, especially in areas of high unmet medical need like Hodgkin lymphoma where patients may be underserved by currently available treatment options."

Source: WSJ

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap